Close Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Close Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45K	Hold	268	–	–	﹤0.01%	176
2026 Q1	$35K	Hold	268	–	–	﹤0.01%	186
2025 Q4	$38K	Hold	268	–	–	﹤0.01%	187
2025 Q3	$38K	Hold	268	–	–	﹤0.01%	183
2025 Q2	$34K	Hold	268	–	–	﹤0.01%	182
2025 Q1	$30K	Hold	268	–	–	﹤0.01%	174
2024 Q4	$37K	Hold	268	–	–	﹤0.01%	162
2024 Q3	$31K	Hold	268	–	–	﹤0.01%	182
2024 Q2	$37K	Hold	268	–	–	﹤0.01%	172
2024 Q1	$37K	Hold	268	–	–	﹤0.01%	169
2023 Q4	$35K	Hold	268	–	–	﹤0.01%	163
2023 Q3	$30K	Hold	268	–	–	﹤0.01%	159
2023 Q2	$25K	Hold	268	–	–	﹤0.01%	185
2023 Q1	$27K	Hold	268	–	–	﹤0.01%	168
2022 Q4	$32K	Hold	268	–	–	﹤0.01%	139
2022 Q3	$28K	Hold	268	–	–	﹤0.01%	133
2022 Q2	$26K	Hold	268	–	–	﹤0.01%	136
2022 Q1	$23K	Hold	268	–	–	﹤0.01%	157
2021 Q4	$23K	Hold	268	–	–	﹤0.01%	157
2021 Q3	$26K	Hold	268	–	–	﹤0.01%	155
2021 Q2	$26K	Hold	268	–	–	﹤0.01%	146
2021 Q1	$26K	Hold	268	–	–	﹤0.01%	153
2020 Q4	$26K	Hold	268	–	–	﹤0.01%	103
2020 Q3	$26K	Hold	268	–	–	﹤0.01%	108
2020 Q2	$33K	Hold	268	–	–	﹤0.01%	110
2020 Q1	$23K	Hold	268	–	–	﹤0.01%	117
2019 Q4	$29K	Hold	268	–	–	﹤0.01%	125
2019 Q3	$24K	Hold	268	–	–	﹤0.01%	131
2019 Q2	$23K	Hold	268	–	–	﹤0.01%	137
2019 Q1	$24K	Sell	268 -1,039,174	-100%	-$86.9M	﹤0.01%	148
2018 Q4	$106M	Buy	1,039,442 +1,039,174	+387,751%	+$99.6M	11.7%	2
2018 Q3	$33K	Sell	268 -100	-27%	-$11.3K	﹤0.01%	141
2018 Q2	$29K	Hold	368	–	–	﹤0.01%	140
2018 Q1	$29K	Hold	368	–	–	﹤0.01%	146
2017 Q4	$29K	Hold	368	–	–	﹤0.01%	141
2017 Q3	$23K	Hold	368	–	–	﹤0.01%	142
2017 Q2	$17K	Hold	368	–	–	﹤0.01%	159
2017 Q1	$16K	Hold	368	–	–	﹤0.01%	157
2016 Q4	$14K	Buy	+368	New	+$16.7K	﹤0.01%	122

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Close Asset Management's NBIX Position: Q2 2026 in Review

Close Asset Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 268 shares worth $45K. The position accounts for ﹤0.01% of the portfolio, ranked #176.

Close Asset Management first reported a position in NBIX in Q4 2016 and has held it in 39 quarters since. The position peaked at $106M in Q4 2018. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Close Asset Management held 268 shares of Neurocrine Biosciences worth $45K as of Q2 2026.
Close Asset Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #176 holding.
Close Asset Management first reported a position in Neurocrine Biosciences in Q4 2016 and has held it in 39 quarters since.
Close Asset Management's Neurocrine Biosciences position peaked at $106M in Q4 2018.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.